Loco was right all along. Give credit when credit is due. Big news next week from teva on possible new partnerships. I wonder how many of the 15 new drug combinations will include Antares? It seems the markets are awakening to this news which was released just 7 hours ago.
One thing mentioned at the conference call by Paul that no one seemed to pick up on was the statement that now that Antares has a sales force Antares has already been approached by small pharmaceutical companies with out a sales force in place to license with Antares to sell their drugs . We are getting there people. We are on our way to making big bucks on Antares. GLT
Listen guys and ladies , I've been in this stock for over three years now and whether we like it or not the bottom line is Antares is for sale for under $4 post approval. The market will tell us when it's oversold and exactly what the street wants to value it until it gets some data on oxy sales Good luck everyone I am holding to the end
The institutions that bought the public offering in Oct of 2012 for $4 and sold today , made a minimum of 17% in one year which is not too shabby. 12 million shares trading over $4.6 is a nice base to move up from steadily over time. GLT
The FDA says it would continue with advisory committee meetings,at which expert panelists make recommendations on whether the agency should approve a particular product but these meetings could be conducted in less conventional formats.
In order to prevent government from closing down there is a real good chance that the medical device tax will be repealed .The republicans have attached it to the government spending bill. will that affect Antares in a positive way if passed?
I am coming to the belief that as many shares as possible are being accumulated at $4 by a buyer of the company, who will make an offer, soon after FDA approval.The more shares obtained at $4, the lower the overall cost to the buyer when they make their tender.
an institution may have taken profits and now is back accumulating at a lower level for the longer term
There is obviously an open buy order for all shares that come available at $4. We just experienced a pre-announcement approval sell-off with a subsequent accumulation prior to run-up instead of a post approval sell-off after an overbought situation developed prior to approval In other words these players are in for the long term.